Incyte (LTS:0J9P) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0J9P Incyte Corp LTS:0J9P
91 GF Score
Price $114.76
GF Value $99.82
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0J9P
91GF Score
Incyte Corp LTS:0J9P
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (LTS:0J9P) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of $114.76 is trading 15% above its estimated GF Value™ of $99.82. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for LTS:0J9P:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $99.82 vs. price of $114.76 (15% above fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the LTS:0J9P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
91GF Score

Get the complete analysis for LTS:0J9P

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$114.76
Price
$99.82
GF Value